Pharmacokinetics and pharmacodynamics of dasatinib in the chronic phase of newly diagnosed chronic myeloid leukemia

被引：0
|
作者：
Yoji Ishida
Kazunori Murai
Kohei Yamaguchi
Takuto Miyagishima
Motohiro Shindo
Kazuei Ogawa
Takahiro Nagashima
Shinji Sato
Reiko Watanabe
Satoshi Yamamoto
Takayuki Hirose
Souich Saitou
Masakatsu Yonezumi
Takeshi Kondo
Yuichi Kato
Noboru Mochizuki
Keiko Ohno
Satoshi Kishino
Kohmei Kubo
Tatsuo Oyake
Shigeki Ito
机构：
[1] Iwate Medical University School of Medicine,Saitama Medical Center
[2] Aomori Prefectural Central Hospital,Department of Hematology and Oncology, Internal Medicine
[3] Kushiro Rosai Hospital,undefined
[4] Asahikawa Medical University School of Medicine,undefined
[5] Fukushima Medical University School of Medicine,undefined
[6] Kitami Red Cross Hospital,undefined
[7] Okitama Public General Hospital,undefined
[8] Saitama Medical University,undefined
[9] Sapporo City General Hospital,undefined
[10] Niigata Cancer Center Hospital,undefined
[11] Nihonkai General Hospital,undefined
[12] Hokkaido Cancer Center,undefined
[13] Hokkaido University School of Medicine,undefined
[14] Yamagata University Faculty of Medicine,undefined
[15] Meiji Pharmaceutical University,undefined
[16] Iwate Medical University School of Medicine,undefined
来源：
European Journal of Clinical Pharmacology | 2016年 / 72卷
关键词：
Dasatinib; Phamacokinetics; Pharmacodynamics; Molecular response; Half maximal inhibitory concentration;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：185 / 193
页数：8
相关论文
共 50 条
  • [1] Pharmacokinetics and pharmacodynamics of dasatinib in the chronic phase of newly diagnosed chronic myeloid leukemia
    Ishida, Yoji
    Murai, Kazunori
    Yamaguchi, Kohei
    Miyagishima, Takuto
    Shindo, Motohiro
    Ogawa, Kazuei
    Nagashima, Takahiro
    Sato, Shinji
    Watanabe, Reiko
    Yamamoto, Satoshi
    Hirose, Takayuki
    Saitou, Souich
    Yonezumi, Masakatsu
    Kondo, Takeshi
    Kato, Yuichi
    Mochizuki, Noboru
    Ohno, Keiko
    Kishino, Satoshi
    Kubo, Kohmei
    Oyake, Tatsuo
    Ito, Shigeki
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 72 (02) : 185 - 193
  • [2] Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia
    Jabbour, Elias
    Haddad, Fadi G.
    Sasaki, Koji
    Carter, Bing Z.
    Alvarado, Yesid
    Nasnas, Cedric
    Nasr, Lewis
    Masarova, Lucia
    Daver, Naval
    Pemmaraju, Naveen
    Short, Nicholas J.
    Skinner, Jeffrey
    Kadia, Tapan
    Borthakur, Gautam
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Issa, Ghayas C.
    Andreeff, Michael
    Kantarjian, Hagop
    CANCER, 2024, 130 (15) : 2652 - 2659
  • [3] CORRELATION OF DASATINIB PHARMACOKINETICS WITH CLINICAL RESPONSE AND ADVERSE EVENTS IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA CHRONIC PHASE
    Mita, A.
    Miura, M.
    Niioka, T.
    Abumiya, M.
    Kobayasi, T.
    Takahshi, S.
    Kameoka, Y.
    Yoshioka, T.
    Takahashi, N.
    HAEMATOLOGICA, 2015, 100 : 694 - 694
  • [4] Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
    Kantarjian, Hagop
    Shah, Neil P.
    Hochhaus, Andreas
    Cortes, Jorge
    Shah, Sandip
    Ayala, Manuel
    Moiraghi, Beatriz
    Shen, Zhixiang
    Mayer, Jiri
    Pasquini, Ricardo
    Nakamae, Hirohisa
    Huguet, Francoise
    Boque, Concepcion
    Chuah, Charles
    Bleickardt, Eric
    Bradley-Garelik, M. Brigid
    Zhu, Chao
    Szatrowski, Ted
    Shapiro, David
    Baccarani, Michele
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (24): : 2260 - 2270
  • [5] Clinical Efficacy and Safety Of Dasatinib For Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase In Japan
    Yamaguchi, Kohei
    Murai, Kazunori
    Ito, Shigeki
    Akagi, Tomoaki
    Ogawa, Kazuei
    Meguro, Kuniaki
    Inomata, Mitsue
    Watanabe, Reiko
    Miyagishima, Takuto
    Wakasa, Kentaro
    Shindo, Motohiro
    Tsukushi, Yasuhiko
    Kubo, Kohmei
    Ishida, Yoji
    BLOOD, 2013, 122 (21)
  • [6] Attenuated Dose Dasatinib in Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase Patients in India.
    Ahmed, Rayaz
    Singh, Reema
    Kapoor, Jyotsna
    Patra, Pritish Chandra
    Agrawal, Narendra
    Bhurani, Dinesh
    Halder, Rohan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (02): : E71 - E77
  • [7] Pharmacokinetics of generic dasatinib in the management of chronic myeloid leukemia in the chronic phase
    孔军
    China Medical Abstracts(Internal Medicine), 2017, 34 (01) : 53 - 54
  • [8] Efficacy and Safety of Generic Dasatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: A Multicenter in China
    Yu, Wenjuan
    Du, Xin
    Wang, Weiguang
    Lou, Jin
    Liu, Peng
    Meng, Li
    Jin, Jie
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (09): : E867 - E873
  • [9] Dasatinib: From Treatment of Imatinib-Resistant or -Intolerant Patients With Chronic Myeloid Leukemia to Treatment of Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
    Abbott, Brian L.
    CLINICAL THERAPEUTICS, 2012, 34 (02) : 272 - 281
  • [10] Is 50 mg/day the new standard dose of dasatinib in newly diagnosed patients with chronic myeloid leukemia in chronic phase?
    Saydan, Betuel
    Ozmen, Deniz
    Eskazan, Ahmet Emre
    EXPERT REVIEW OF HEMATOLOGY, 2024, 17 (07) : 275 - 277
12345